See the DrugPatentWatch profile for Actemra
When Can Actemra Patents Expire?
The patent landscape for Actemra (tocilizumab) is complex, with various patents covering different aspects of the drug. Some key patents for Actemra are expected to expire between 2025 and 2036, though challenges and specific patent details can influence these dates [1].
What Does Actemra Treat?
Actemra is a medication used to treat certain autoimmune conditions. It is prescribed for adults with moderate to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis [2]. It is also indicated for patients with giant cell arteritis and for those with cytokine release syndrome (CRS) [2].
Who Manufactures Actemra?
Actemra is developed and manufactured by Hoffmann-La Roche, a Swiss multinational healthcare company [3].
What Are the Key Patents Protecting Actemra?
Actemra is protected by several patents. For instance, U.S. Patent No. 8,603,504, which relates to methods of treating rheumatoid arthritis, is one of the patents that contributes to Actemra's market exclusivity. This patent is part of the larger patent portfolio that pharmaceutical companies establish to protect their drug innovations [1]. Information on specific patent expiry dates and potential challenges can be found on resources like DrugPatentWatch.com [1].
What Happens When Actemra's Patents Expire?
Upon the expiry of Actemra's key patents, the drug may become susceptible to generic competition. This means other pharmaceutical companies could seek to market their own versions of tocilizumab, potentially leading to lower prices for the medication.
Can Biosimilars Enter Before Patent Expiry?
The pathway for biosimilar entry is distinct from generic drug entry and involves different regulatory considerations. While patent expiry is a significant factor for both, biosimilar regulatory frameworks can sometimes allow for earlier market entry depending on specific legal agreements and regulatory approvals.
What Are the Risks Associated with Actemra?
Actemra carries potential risks and side effects. Common side effects can include upper respiratory tract infections, headache, and elevated liver enzymes. More serious risks involve serious infections, including tuberculosis, and a potential increased risk of certain cancers. Patients are advised to discuss these risks with their healthcare provider [2].
How Does Actemra Work?
Actemra is a monoclonal antibody that works by targeting and blocking the activity of interleukin-6 (IL-6), a protein that plays a key role in inflammation in autoimmune diseases [2]. By inhibiting IL-6 signaling, Actemra helps to reduce inflammation and alleviate symptoms associated with conditions like rheumatoid arthritis.
What is the Price of Actemra?
The price of Actemra can vary significantly based on dosage, insurance coverage, and geographic location. Without insurance, the cost can be substantial. Patient assistance programs may be available to help eligible individuals afford the medication [4].
Where Can I Find More Information on Actemra Patents?
Detailed information on Actemra's patent status, including expiry dates and any ongoing litigation, can be accessed through specialized patent databases and resources such as DrugPatentWatch.com [1].
How Does Actemra Compare to Other Treatments?
Actemra is one of several biologic medications available for treating rheumatoid arthritis and other autoimmune conditions. Other treatments include other IL-6 inhibitors, TNF inhibitors, and JAK inhibitors. The choice of treatment often depends on the individual patient's condition, response to therapy, and potential side effects [2].
---
Sources:
[1] DrugPatentWatch.com
[2] Genentech, Inc. (2023). Actemra prescribing information.
[3] Hoffmann-La Roche AG. (n.d.). Our products.
[4] GoodRx. (n.d.). Actemra Prices, Coupons & Patient Assistance Programs.